Back to top

Sino Biopharm Wins NMPA Approval for New First-Line Lung Cancer Regimen

Sino Biopharmaceutical ( ($HK:1177) ) has provided an update. Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured approval from China...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Sino Biopharmaceutical (SBMFF)